Our Science – SB Website
Surgery Branch
Selected Links |
 |
| • - Clinical Trials for Melanoma: |
|
| • NCI-07-C-0176: Young TIL - This phase II trial is studying the effectiveness of the administration of tumor-infiltrating lymphocytes together with high-dose aldesleukin after cyclophosphamide and fludarabine in patients with metastatic melanoma. |
|
| • NCI-08-C-0162: Adjuvant F5 T Cells - This randomized phase II trial is studying the effectiveness of gene-modified T lymphocytes for the treatment of patients with high-risk melanoma. |
|
| • NCI-09-C-0051: 600 TBI TCR PBL - The purpose of this phase II trial is to evaluate the safety and effectiveness of the chemotherapy, radiation, anti-MART-1 and anti-gp100 cells, peptide vaccines and IL-2 for treating patients with advanced melanoma. |
|
| •
- Clinical Trial for Kidney Cancer:
|
|
| • NCI-09-C-0092: Renal 2G-1 - The purpose of this trial is to evaluate the safety and effectiveness of targeted DR4 and TRAIL (two proteins found on the surface of many kidney tumors) for the treatment of kidney cancer. |
|
| • - Clinical Trials for Various Cancers: |
|
| • NCI-08-C-0121: ESO TCR PBL - This phase II trial is studying the effectiveness of cell transfer therapy plus high-dose aldesleukin for the treatment of patients with metastatic cancer. |
|
| • NCI-09-C-0047: CEA TCR PBL - The purpose of this phase II trial is to determine whether advanced cancers that express the CEA antigen can be treated effectively with lymphocytes (white blood cells) that have been genetically engineered to contain an anti-CEA protein. |
|
| • NCI-09-C-0082: CD19 CAR PBL - The purpose of this phase I/II trial is to determine the safety and effectiveness of anti-CD19 cells created through gene therapy in patients with B cell lymphomas and leukemias. |
|
| • More Clinical Trials |
|
This page was last updated on 9/8/2009.
